Overview

3BNC117-LS First-in-Human Phase 1 Study

Status:
Completed

Trial end date:
2020-12-31

Target enrollment:

Participant gender:

Summary

The proposed study is a phase 1 study of the mAb 3BNC117-LS administered intravenously in HIV uninfected individuals and HIV-infected individuals, and subcutaneously in HIV-uninfected individuals.The objectives of the study are to evaluate the safety, tolerability and pharmacokinetics of a single administration of 3BNC117-LS.

Phase:

Phase 1

Details

Lead Sponsor:

Rockefeller University

Treatments:

Antibodies